About the company

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.